Prot #R3767‐ONC‐2055: A Phase 3 Trial of Fianlimab (anti‐LAG‐3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High‐risk Melanoma

Project: Research project

Project Details

StatusActive
Effective start/end date9/19/23 → 9/19/26

Funding

  • Parexel (Prot #R3767-ONC-2055 // Prot #R3767-ONC-2055)
  • Regeneron Pharmaceuticals, Inc. (Prot #R3767-ONC-2055 // Prot #R3767-ONC-2055)